Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Juvise Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"The French Specialty Pharmaceutical Company Juvis\u00e9 Pharmaceuticals Has Successfully Completed a \u20ac400M Refinancing Following the Acquisition of The Worldwide Rights of Pylera\u00ae, An Antimicrobial Tri-Therapy Indicated for Gastro-Intestinal Helicobacter Pylor","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches First Generic Version of Pylera\u00ae (Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hydrochloride) Capsules","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for MolPort-001-794-633

    Menu

    MolPort-001-794-633

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Endo International

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo Launches First Generic Version of Pylera® (Bismuth Subcitrate Potassium, Metronidazole, Tetracycline Hydrochloride) Capsules

              Details:

              Bismuth subcitrate potassium and antibacterial agents (metronidazole and tetracycline hydrochloride) capsules in combination are indicated for treating H.pylori infection and duodenal ulcer disease to eradicate H. pylori.

              Lead Product(s): Bismuth Potassium Citrate,Metronidazole,Tetracycline

              Therapeutic Area: Infections and Infectious Diseases Product Name: Pylera-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Juvise Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              The French Specialty Pharmaceutical Company Juvisé Pharmaceuticals Has Successfully Completed a €400M Refinancing Following the Acquisition of The Worldwide Rights of Py...

              Details:

              Pylera®, a 3-in-1 combination of antimicrobial products, is indicated for the treatment of patients with Helicobacter pylori infection suffering from gastro-duodenal ulcer disease.

              Lead Product(s): Bismuth Potassium Citrate,Metronidazole,Tetracycline

              Therapeutic Area: Infections and Infectious Diseases Product Name: Pylera

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: AbbVie Inc

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition July 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Suanfarma Tetracycline
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Close
              4
              Post Enquiry
              POST ENQUIRY